Injectsense
Financials
Estimates*
USD | 2021 | 2022 | 2023 |
---|---|---|---|
Revenues | 1.2m | 1.2m | 1.1m |
% growth | - | - | (7 %) |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $9.8m | Early VC | |
N/A | $3.4m | Series B | |
* | $1.7m | Grant | |
* | N/A | $2.5m Valuation: $49.0m | Late VC |
Total Funding | AUD26.9m |
Related Content
Recent News about Injectsense
EditInjectsense operates at the intersection of advanced semiconductor technology and medical systems, specializing in the development of implantable sensors for continuous medical monitoring. The company's core product is a high-value, miniaturized device that provides reliable, precise, and continuous data transmission to help physicians determine the best course of treatment. Injectsense serves healthcare providers and medical institutions, focusing on improving disease outcomes through evidence-supported therapies. The company partners with major strategic players in the medical field to enhance its technology and expand its market reach. Injectsense's business model revolves around the sale and support of its implantable devices, generating revenue through direct sales and strategic partnerships. The company operates primarily in the medical technology market and aims to change the standard of care with its innovative solutions.
Keywords: implantable sensors, semiconductor technology, medical monitoring, continuous data, precision, healthcare, disease outcomes, strategic partnerships, medical devices, innovation.